Vanguard Group Inc Global Blood Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $8.51 Million - $17.9 Million	262,742 Added 4.36%	6,282,173 $428 Million
Q2 2022 Aug 12, 2022	SELL	$22.3 - $37.39 $107,731 - $180,631	-4,831 Reduced 0.08%	6,019,431 $192 Million
Q1 2022 May 13, 2022	BUY	$25.68 - $35.59 $799,161 - $1.11 Million	31,120 Added 0.52%	6,024,262 $209 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $4.45 Million - $7.2 Million	178,743 Added 3.07%	5,993,142 $175 Million
Q3 2021 Nov 12, 2021	SELL	$25.48 - $37.34 $1.23 Million - $1.8 Million	-48,220 Reduced 0.82%	5,814,399 $148 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $190 Million - $255 Million	5,862,619 New	5,862,619 $205 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.